Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Barclays PLC due to allegations of materially misleading business information issued by Barclays [1]. Group 1: Legal Action and Compensation - Investors who purchased Barclays securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to Barclays [2]. Group 2: Market Impact and Exposure - On February 27, 2026, a Reuters article highlighted concerns in the banking sector following the collapse of UK mortgage provider Market Financial Solutions Ltd, which reportedly had a £600 million ($809.70 million) exposure to Barclays [3]. - Following this news, Barclays American Depositary Shares experienced a decline of 3.99% on February 27, 2026, and an additional 2.3% on March 2, 2026 [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, noting its own achievements in recovering hundreds of millions for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a record settlement against a Chinese company and being ranked No. 1 by ISS Securities Class Action Services in 2017 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PomDoctor Ltd. securities between October 9, 2025, and December 11, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought PomDoctor securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff [2]. - The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme, including misinformation on social media and the use of offshore accounts for share dumping [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3].

Group 1 - The Rosen Law Firm is reminding purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc (NASDAQ: MREO) about the April 6, 2026 lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Mereo ADSs during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][7] Group 2 - The lawsuit alleges that Mereo BioPharma provided misleading information regarding the expected results of the Phase 3 Orbit and COSMIC studies for setrusumab in Osteogenesis Imperfecta (OI) [5] - Defendants are accused of making positive statements about setrusumab's efficacy while concealing adverse facts about the Phase 3 programs, which did not meet their primary endpoints [6] - The misleading statements led to investors purchasing Mereo's ADSs at inflated prices, resulting in damages when the true information became public [6]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Lakeland Industries, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on April 24, 2026 [1]. Group 1: Class Action Details - Investors who bought Lakeland securities between December 1, 2023, and December 9, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by April 24, 2026 [3]. Group 2: Case Allegations - The lawsuit alleges that Lakeland's management made false and misleading statements regarding the performance of its Pacific Helmets and Jolly businesses, including issues with shipping delays, production problems, and a slower rollout of new products [5]. - It is claimed that the defendants overstated the positive impact of these businesses on Lakeland's financial results and the overall strength of operations [5]. - The lawsuit also points out that Lakeland's financial results were deteriorating due to tariff-related challenges, certification delays, and material flow issues, leading to unreliable financial guidance from the company [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Plug Power Inc. securities between January 17, 2025, and November 13, 2025, of the April 3, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Plug Power securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by April 3, 2026, to serve as lead plaintiff, representing other class members [2] - The lawsuit alleges that defendants made false or misleading statements regarding the availability of funds from the U.S. Department of Energy and the construction of hydrogen production facilities, leading to investor damages when the truth was revealed [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors, including over $438 million in 2019 [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PayPal Holdings, Inc. common stock between February 25, 2025, and February 2, 2026, of the April 20, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought PayPal common stock during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is April 20, 2026, with the lead plaintiff representing other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Background - The lawsuit alleges that PayPal's defendants provided misleading information regarding the company's financial targets for 2027 and the growth potential of its Branded Checkout segment [5]. - It is claimed that while presenting an optimistic outlook, the defendants concealed material adverse facts about the salesforce's capability to meet growth expectations, leading to investor damages when the truth emerged [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased PomDoctor Ltd. securities between October 9, 2025, and December 11, 2025, of the April 7, 2026, deadline to become lead plaintiffs in a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought PomDoctor securities during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by April 7, 2026, to serve as lead plaintiff [2]. - The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme, including misinformation on social media and the use of offshore accounts for share dumping [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Aquestive Therapeutics, Inc. for the period between June 16, 2025, and January 8, 2026, due to alleged misleading statements regarding the company's New Drug Application for Anaphylm [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Aquestive made false and/or misleading statements and failed to disclose the true state of its New Drug Application for Anaphylm, particularly regarding the human factors involved in the use of its sublingual film [5]. - Investors who purchased Aquestive securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by May 4, 2026, to represent other class members in directing the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 7, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, defendants made false and misleading statements regarding Inovio's CELLECTRA device manufacturing deficiencies [5]. - It is claimed that Inovio was unlikely to submit the INO-3107 Biologics License Application to the FDA by the second half of 2024 due to insufficient information to justify its eligibility for accelerated approval or priority review [5]. - The lawsuit asserts that the overall regulatory and commercial prospects of INO-3107 were overstated, leading to materially false and misleading public statements [5].

New York, New York--(Newsfile Corp. - March 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2026.SO WHAT: If you purchased Soleno common stock during ...